These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 11212474)
1. Use of a subcutaneous syringe driver in epidermolysis bullosa. O'Neill B; Lucas C; Gannon C Palliat Med; 2001 Jan; 15(1):77-8. PubMed ID: 11212474 [No Abstract] [Full Text] [Related]
2. Gabapentin as part of multimodal analgesia in a newborn with epidermolysis bullosa. Allegaert K; Naulaers G Paediatr Anaesth; 2010 Oct; 20(10):972-3. PubMed ID: 20849513 [No Abstract] [Full Text] [Related]
3. The use of syringe drivers in palliative care. Gomez Y Aust Nurs J; 2000 Aug; 8(2):suppl 1-3. PubMed ID: 11894458 [No Abstract] [Full Text] [Related]
4. Continuous subcutaneous infusions of opiates in cancer patients with pain. Coyle N; Mauskop A; Maggard J; Foley KM Oncol Nurs Forum; 1986; 13(4):53-7. PubMed ID: 2873557 [No Abstract] [Full Text] [Related]
5. Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases. Schräder NHB; Duipmans JC; Molenbuur B; Wolff AP; Jonkman MF Br J Dermatol; 2019 Apr; 180(4):922-924. PubMed ID: 30347109 [TBL] [Abstract][Full Text] [Related]
6. Epidermolysis bullosa pruriginosa showing good response to low-dose thalidomide - a report of two cases. Ranugha PS; Mohanan S; Chandrashekar L; Basu D; Thappa DM; Rajesh NG Dermatol Ther; 2014; 27(1):60-3. PubMed ID: 24502315 [TBL] [Abstract][Full Text] [Related]
7. Subcutaneous infusions--a medical last rite. O'Neill WM Palliat Med; 1994; 8(2):91-3. PubMed ID: 7521722 [No Abstract] [Full Text] [Related]
8. The use of the syringe driver in terminal care. Oliver DJ Br J Clin Pharmacol; 1985 Nov; 20(5):515-6. PubMed ID: 4074624 [No Abstract] [Full Text] [Related]
9. Subcutaneous opioid infusion. Pasero C Am J Nurs; 2002 Jul; 102(7):61-2. PubMed ID: 12394060 [No Abstract] [Full Text] [Related]
10. Controlling breakthrough pain in palliative care. Evans N; Palmer A Nurs Stand; 1998 Nov 4-10; 13(7):53-4. PubMed ID: 9919202 [TBL] [Abstract][Full Text] [Related]
11. [Phenytoin therapy in recessive dystrophic epidermolyses (epidermolysis bullosa dystrophica type Hallopeau-Siemens and epidermolysis bullosa dystrophica inversa)]. Wirth H; Nesch A; Ostapowicz B; Anton-Lamprecht I Z Hautkr; 1983 Apr; 58(8):555-74. PubMed ID: 6858283 [TBL] [Abstract][Full Text] [Related]
12. [The effect of collagenase inhibition on bullous eruption and healing process in epidermolysis bullosa]. Coradello H; Lubec G Hautarzt; 1979 Feb; 30(2):89-91. PubMed ID: 217851 [TBL] [Abstract][Full Text] [Related]
13. Acquired epidermolysis bullosa treated with a gold compound. Livden JK; Nilsen R Acta Derm Venereol; 1979; 59(4):378-9. PubMed ID: 92161 [TBL] [Abstract][Full Text] [Related]
14. Assessment of a treatment for epidermolysis bullosa. Haber RM; Ramsay CA; Boxall LB Can Med Assoc J; 1984 Jul; 131(1):10-11, 14. PubMed ID: 6733642 [No Abstract] [Full Text] [Related]
15. [Epidermolysis bullosa hereditaria]. Jovanović M; Rasić D; Stojanović D Srp Arh Celok Lek; 1968 Mar; 96(3):323-7. PubMed ID: 5192204 [No Abstract] [Full Text] [Related]
16. The immunopathology of epidermolysis bullosa acquisita. Kushniruk W Can Med Assoc J; 1973 May; 108(9):1143-6. PubMed ID: 4574408 [TBL] [Abstract][Full Text] [Related]